New combo therapy aims to boost immune system against deadly brain cancer
NCT ID NCT04817254
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 35 times
Summary
This phase 2 trial tested whether adding immune checkpoint inhibitors (nivolumab and ipilimumab) to standard chemotherapy (temozolomide) improves survival in 47 adults with newly diagnosed glioblastoma or gliosarcoma. Participants had their tumors surgically removed and completed initial chemoradiation before starting the study treatment. The goal was to see if changes in immune cells in the blood relate to better outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab, ipilimumab, and temozolomide
What this could lead to
If successful, this could point toward a more effective treatment approach for glioblastoma by using the immune system to fight the tumor.
What could go wrong
This is a small, early-phase trial with only 47 participants, so results may not apply to everyone. Immune checkpoint inhibitors can cause serious side effects like inflammation in healthy organs.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.